EULAV Asset Management’s Biogen BIIB Stock Holding History

EULAV Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-37,015	Closed	-$10.5M	–	229
2021 Q3	$10.5M	Buy	37,015 +15	+0%	+$4.92K	0.28%	102
2021 Q2	$12.8M	Buy	+37,000	New	+$11.2M	0.34%	93
2020 Q1	–	Sell	-25,000	Closed	-$7.42M	–	258
2019 Q4	$7.42M	Buy	+25,000	New	+$6.94M	0.26%	104
2019 Q1	–	Sell	-32,000	Closed	-$9.63M	–	306
2018 Q4	$9.63M	Sell	32,000 -6,000	-16%	-$1.91M	0.48%	68
2018 Q3	$13.4M	Buy	38,000 +8,000	+27%	+$2.75M	0.58%	61
2018 Q2	$8.71M	Sell	30,000 -3,000	-9%	-$843K	0.4%	85
2018 Q1	$9.04M	Sell	33,000 -6,000	-15%	-$1.86M	0.43%	76
2017 Q4	$12.4M	Buy	39,000 +7,500	+24%	+$2.41M	0.59%	51
2017 Q3	$9.86M	Sell	31,500 -500	-2%	-$148K	0.47%	72
2017 Q2	$8.68M	Sell	32,000 -4,000	-11%	-$1.06M	0.43%	75
2017 Q1	$9.84M	Sell	36,000 -2,000	-5%	-$565K	0.5%	64
2016 Q4	$10.8M	Buy	38,000 +8,000	+27%	+$2.37M	0.58%	58
2016 Q3	$9.39M	Sell	30,000 -4,500	-13%	-$1.33M	0.5%	75
2016 Q2	$8.34M	Sell	34,500 -500	-1%	-$132K	0.46%	78
2016 Q1	$9.11M	Sell	35,000 -6,000	-15%	-$1.58M	0.51%	71
2015 Q4	$12.6M	Sell	41,000 -1,000	-2%	-$287K	0.69%	47
2015 Q3	$12.3M	Buy	42,000 +5,000	+14%	+$1.65M	0.7%	43
2015 Q2	$14.9M	Buy	37,000 +5,000	+16%	+$2.01M	0.78%	29
2015 Q1	$13.5M	Hold	32,000	–	–	0.7%	37
2014 Q4	$10.9M	Buy	32,000 +15,000	+88%	+$4.85M	0.58%	58
2014 Q3	$5.62M	Buy	17,000 +5,000	+42%	+$1.65M	0.31%	128
2014 Q2	$3.78M	Buy	12,000 +2,000	+20%	+$602K	0.2%	161
2014 Q1	$3.06M	Hold	10,000	–	–	0.17%	188
2013 Q4	$2.8M	Hold	10,000	–	–	0.15%	199
2013 Q3	$2.41M	Sell	10,000 -1,500	-13%	-$336K	0.14%	216
2013 Q2	$2.48M	Buy	+11,500	New	+$2.46M	0.15%	216

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

EULAV Asset Management's BIIB Position: Q4 2021 in Review

EULAV Asset Management sold out of Biogen (BIIB) in Q4 2021, closing a stake of 37,015 shares — an estimated $10.5M sold.

EULAV Asset Management first reported a position in BIIB in Q2 2013 and held it in 26 quarters. The position peaked at $14.9M in Q2 2015. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

EULAV Asset Management reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
EULAV Asset Management sold 37,015 Biogen shares in Q4 2021, an estimated $10.5M.
EULAV Asset Management first reported a position in Biogen in Q2 2013 and held it in 26 quarters.
EULAV Asset Management's Biogen position peaked at $14.9M in Q2 2015.
1,010 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on EULAV Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.